UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Factor VIII assay variability in postinfusion samples containing full length and B-domain deleted FVIII

Haemophilia : the official journal of the World Federation of Hemophilia, 2016-09, Vol.22 (5), p.806-812

2016

Volltextzugriff (PDF)

Plasma‐derived FVIII/VWF complex shows higher protection against inhibitors than isolated FVIII after infusion in haemophilic patients: A translational study

Haemophilia : the official journal of the World Federation of Hemophilia, 2022-09, Vol.28 (5), p.737-744

2022

Volltextzugriff (PDF)

Accurate measurement of extended half‐life and unmodified factor VIII low levels with one‐stage FVIII assays is dependent on the matrix of calibration curves

Haemophilia : the official journal of the World Federation of Hemophilia, 2019-01, Vol.25 (1), p.e19-e26

2019

Volltextzugriff (PDF)

Modulating the microenvironment during FVIII uptake influences the nature of FVIII-peptides presented by antigen-presenting cells

Frontiers in immunology, 2022-10, Vol.13, p.975680-975680

2022

Volltextzugriff (PDF)

Report on 4 cases with decreased recovery due to neutralizing antibodies specific for PEGylated recombinant factor VIII

Journal of thrombosis and haemostasis, 2023-10, Vol.21 (10), p.2771-2775

2023

Volltextzugriff (PDF)

A world-wide survey and field study in clinical haemostasis laboratories to evaluate FVIII:C activity assay variability of ADYNOVATE and OBIZUR in comparison with ADVATE

Haemophilia : the official journal of the World Federation of Hemophilia, 2016-11, Vol.22 (6), p.957-965

2016

Volltextzugriff (PDF)

Flow-Cytometry Platform for Intracellular Detection of FVIII in Blood Cells: A New Tool to Assess Gene Therapy Efficiency for Hemophilia A

Molecular therapy. Methods & clinical development, 2020-06, Vol.17, p.1-12

2020

Volltextzugriff (PDF)

Prophylaxis for hemophilia A without inhibitors: treatment options and considerations

Expert review of hematology, 2020-07, Vol.13 (7), p.731-743

2020

Volltextzugriff (PDF)

Porcine recombinant factor VIII (Obizur; OBI-1; BAX801): product characteristics and preclinical profile

Haemophilia : the official journal of the World Federation of Hemophilia, 2016-03, Vol.22 (2), p.308-317

2016

Volltextzugriff (PDF)

Measuring FVIII activity of glycopegylated recombinant factor VIII, N8‐GP, with commercially available one‐stage clotting and chromogenic assay kits: a two‐centre study

Haemophilia : the official journal of the World Federation of Hemophilia, 2017-05, Vol.23 (3), p.458-465

2017

Volltextzugriff (PDF)

Perspective – The case for zero bleeds and drug bioequivalence in the treatment of congenital hemophilia A in 2021

Blood reviews, 2021-11, Vol.50, p.100849-100849, Article 100849

2021

Volltextzugriff (PDF)

von Willebrand factor contributes to longer half-life of PEGylated factor VIII in vivo

Haemophilia : the official journal of the World Federation of Hemophilia, 2013-07, Vol.19 (4), p.539-545

2013

Volltextzugriff (PDF)

Factor VIII inhibitors in hemophilia A: rationale and latest evidence

Therapeutic advances in hematology, 2013-02, Vol.4 (1), p.59-72

2013

Volltextzugriff (PDF)

Measurement of B‐domain‐deleted ReFacto AF activity with a product‐specific standard is affected by choice of reagent and patient‐specific factors

Haemophilia : the official journal of the World Federation of Hemophilia, 2018-07, Vol.24 (4), p.675-682

2018

Volltextzugriff (PDF)

No immunological changes after factor VIII product switch: An in depth analysis in haemophilia A patients

Haemophilia : the official journal of the World Federation of Hemophilia, 2023-07, Vol.29 (4), p.1039-1048

2023

Volltextzugriff (PDF)

Extended half‐life pegylated, full‐length recombinant factor VIII for prophylaxis in children with severe haemophilia A

Haemophilia : the official journal of the World Federation of Hemophilia, 2017-03, Vol.23 (2), p.238-246

2017

Volltextzugriff (PDF)

Overshoot of FVIII activity in patients with acquired hemophilia A who achieve complete remission

International journal of hematology, 2020-04, Vol.111 (4), p.544-549

2020

Volltextzugriff (PDF)

Molecular therapeutics of hemophilia A and B

Expert review of hematology, 2022-05, Vol.15 (5), p.431-441

2022

Volltextzugriff (PDF)

Validación de un método para la cuantificación plasmática de emicizumab

Hematología (En línea), 2023, Vol.27 (3), p.16-26

2023

Volltextzugriff (PDF)

Cuantificación plasmática de emicizumab

Hematología (En línea), 2022-12, Vol.26 (3), p.96-98

2022

Volltextzugriff (PDF)

An update of the current pharmacotherapeutic armamentarium for hemophilia A

Expert opinion on pharmacotherapy, 2022-01, Vol.23 (1), p.129-138

Mahlangu, Johnny

2022

Volltextzugriff (PDF)

Clinical utility of sample preheat treatment in a modified Nijmegen‐Bethesda assay (mNBA) for inhibitor monitoring in congenital and acquired haemophilia A: A single‐centre four‐year experience

Haemophilia : the official journal of the World Federation of Hemophilia, 2020-11, Vol.26 (6), p.e300-e307

2020

Volltextzugriff (PDF)

Analysis of the correlation between body weight, body composition, and factor VIII recovery in paediatric patients with severe haemophilia A – a single-centre study

Pediatria polska, 2023, Vol.98 (3), p.203-207

2023

Volltextzugriff (PDF)

Risk factors for inhibitor development in severe hemophilia A

Thrombosis research, 2018-08, Vol.168, p.20-27

2018

Volltextzugriff (PDF)

Modified clot waveform analysis to measure plasma coagulation potential in the presence of the anti‐factor IXa/factor X bispecific antibody emicizumab

Journal of thrombosis and haemostasis, 2018-06, Vol.16 (6), p.1078-1088

2018

Volltextzugriff (PDF)

1 – 25 von 937

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(809)
Mit Volltextzugriff
(760)

Publikationsform

Artikel
(848)
Buchkapitel
(79)
Berichte
(9)
Bücher
(1)

Sprache

2 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(725)
Life Sciences & Biomedicine
(722)
Humans
(550)
Hematology
(524)
Fviii
(276)
Male
(215)
Hemophilia
(212)
Hemophilia A - Drug Therapy
(203)
Factor Viii - Immunology
(182)
Hemophilia A
(166)
Cardiovascular System & Cardiology
(153)
Peripheral Vascular Disease
(153)
Female
(143)
Haemophilia A
(141)
Factor Viii - Therapeutic Use
(139)
Hemophilia A - Immunology
(138)
Adult
(136)
Factor Viii
(136)
Animals
(130)
Middle Aged
(111)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Factor VIII assay variability in postinfusion samples containing full length and B-domain deleted FVIII

Plasma‐derived FVIII/VWF complex shows higher protection against inhibitors than isolated FVIII after infusion in haemophilic patients: A translational study

Accurate measurement of extended half‐life and unmodified factor VIII low levels with one‐stage FVIII assays is dependent on the matrix of calibration curves

Modulating the microenvironment during FVIII uptake influences the nature of FVIII-peptides presented by antigen-presenting cells

Report on 4 cases with decreased recovery due to neutralizing antibodies specific for PEGylated recombinant factor VIII

A world-wide survey and field study in clinical haemostasis laboratories to evaluate FVIII:C activity assay variability of ADYNOVATE and OBIZUR in comparison with ADVATE

Flow-Cytometry Platform for Intracellular Detection of FVIII in Blood Cells: A New Tool to Assess Gene Therapy Efficiency for Hemophilia A

Prophylaxis for hemophilia A without inhibitors: treatment options and considerations

Porcine recombinant factor VIII (Obizur; OBI-1; BAX801): product characteristics and preclinical profile

Measuring FVIII activity of glycopegylated recombinant factor VIII, N8‐GP, with commercially available one‐stage clotting and chromogenic assay kits: a two‐centre study

Perspective – The case for zero bleeds and drug bioequivalence in the treatment of congenital hemophilia A in 2021

von Willebrand factor contributes to longer half-life of PEGylated factor VIII in vivo

Factor VIII inhibitors in hemophilia A: rationale and latest evidence

Measurement of B‐domain‐deleted ReFacto AF activity with a product‐specific standard is affected by choice of reagent and patient‐specific factors

No immunological changes after factor VIII product switch: An in depth analysis in haemophilia A patients

Extended half‐life pegylated, full‐length recombinant factor VIII for prophylaxis in children with severe haemophilia A

Overshoot of FVIII activity in patients with acquired hemophilia A who achieve complete remission

Molecular therapeutics of hemophilia A and B

Validación de un método para la cuantificación plasmática de emicizumab

Cuantificación plasmática de emicizumab

An update of the current pharmacotherapeutic armamentarium for hemophilia A

Clinical utility of sample preheat treatment in a modified Nijmegen‐Bethesda assay (mNBA) for inhibitor monitoring in congenital and acquired haemophilia A: A single‐centre four‐year experience

Analysis of the correlation between body weight, body composition, and factor VIII recovery in paediatric patients with severe haemophilia A – a single-centre study

Risk factors for inhibitor development in severe hemophilia A

Modified clot waveform analysis to measure plasma coagulation potential in the presence of the anti‐factor IXa/factor X bispecific antibody emicizumab

Suchergebnisse filtern